Startup Dossier
SeaBeLife
Biotechnology company developing innovative small molecules that block two regulated cell death pathways (necroptosis and ferroptosis) to treat severe, rare, and chronic diseases with no current therapeutic alternatives. Lead programs target dry age-related macular degeneration (AMD) and severe acute hepatitis.
About
Biotechnology company developing innovative small molecules that block two regulated cell death pathways (necroptosis and ferroptosis) to treat severe, rare, and chronic diseases with no current therapeutic alternatives. Lead programs target dry age-related macular degeneration (AMD) and severe acute hepatitis.
Structural DNA
Legal Name
SeaBeLife
SIREN
849445192
Founders & Team
Funding Lineage
Seed
iXLife (Lead)
€2.0M
Oct 2025
Seed
Angels Santé (Lead)
€1.2M
Sept 2023
Seed
Ava capital (Lead)
€1.0M
May 2021
Programs
i-Nov
i-Lab